Global Opioid-induced Constipation Market Growth (Status and Outlook) 2023-2029
LPI (LP Information)' newest research report, the “Opioid-induced Constipation Industry Forecast” looks at past sales and reviews total world Opioid-induced Constipation sales in 2022, providing a comprehensive analysis by region and market sector of projected Opioid-induced Constipation sales for 2023 through 2029. With Opioid-induced Constipation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Opioid-induced Constipation industry.
This Insight Report provides a comprehensive analysis of the global Opioid-induced Constipation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Opioid-induced Constipation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Opioid-induced Constipation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Opioid-induced Constipation and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Opioid-induced Constipation.
The global Opioid-induced Constipation market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Opioid-induced Constipation is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Opioid-induced Constipation is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Opioid-induced Constipation is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Opioid-induced Constipation players cover AstraZeneca, Takeda Pharmaceutical, Bausch Health, Abbott, Bayer, Boehringer Ingelheim, C.B. Fleet, Cosmo Pharmaceuticals and Daewoong, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Opioid-induced Constipation market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Solid
Liquid
Segmentation by application
Drugstore
Hospital
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Takeda Pharmaceutical
Bausch Health
Abbott
Bayer
Boehringer Ingelheim
C.B. Fleet
Cosmo Pharmaceuticals
Daewoong
Daiichi Sankyo
GlaxoSmithKline
Ironwood Pharmaceuticals
Johnson and Johnson
Merck
Mundipharma
Nektar Therapeutics
Pfizer
Progenics Pharmaceuticals
Shionogi
SLA Pharma
Sucampo
Synergy Pharmaceuticals
Theravance
Please note: The report will take approximately 2 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook